Introduction {#Sec1}
============

The tripartite motif (TRIM) is a superfamily of proteins conserved throughout the animal kingdom and has spread during vertebrate evolution; there are more than 80 known TRIMs encoded by the human and mouse genomes \[[@CR1]\]. TRIM proteins are involved in many different cellular functions by acting as E3 ubiquitin (E3-Ub) ligases \[[@CR2]--[@CR4]\]. The consensus N-terminal region of TRIM proteins contains a RING finger domain followed by one or two B-box domains and a coiled-coil domain (CC) \[[@CR4]\]. The RING domain comprises conserved cysteine and histidine residues that bind to two zinc atoms in a cross-brace arrangement and is essential for recruiting the E2-conjugated enzyme loaded with ubiquitin (E2 \~ Ub). The CC domain in combination with the B-box domain has been proposed to mediate protein-protein interactions, particularly homomeric and heteromeric interactions and by promoting the formation of interlocking helices between the TRIM family and other protein \[[@CR5], [@CR6]\]. Each TRIM protein has a specific C-terminal domain, which confers substrate specificity via protein-protein interactions \[[@CR3], [@CR7]\]. Most commonly found are the PRY and SPRY domains (B30.2), either in combination (PRY-SPRY) or individually. SPRY domains are found in some human protein families as well and are evolutionarily conserved in mammals, plants, and fungi \[[@CR3]\]. Many TRIM proteins are induced by type I and type II interferons (IFN-I or IFN-II) or pathogen stimulations, in different cell types including human and mouse primary immune cells \[[@CR8], [@CR9]\]. Almost half of human TRIMs can positively regulate induction of IFN-I and/or NF-kB-mediated signaling \[[@CR10], [@CR11]\]. Since IFN signaling leads to induction of multiple IFN-stimulated genes (ISGs) that are known to have direct antiviral effector functions \[[@CR12]\], together these studies suggest that TRIMs may have evolved as defense mechanisms that aid in resistance to pathogens \[[@CR13]--[@CR15]\]. In addition to their immune functions, as expected for enzymes involved in the ubiquitination process, TRIMs are also known to play important roles in a wide range of biological processes, including cell proliferation, differentiation, development, apoptosis, oncogenesis, innate immunity, and DNA repair \[[@CR2], [@CR3]\]. Intriguingly, some viruses have the ability to use TRIMs to improve several steps of the replication cycle and cause pathogenesis \[[@CR4], [@CR16]••, [@CR17]••\].

In this review, we discuss the novel mechanisms that are used by TRIM proteins in the context of their different functions related to host defense, which ultimately may affect virus pathogenesis. We focused our discussion on recent developments and on TRIMs that have been thoroughly studied. Some excellent recent reviews highlight the roles of other TRIMs \[[@CR3]--[@CR5], [@CR13]--[@CR15], [@CR18]--[@CR29]\].

Antiviral Activity of TRIM Proteins {#Sec2}
===================================

There are host factors that have the capability of blocking virus replication at almost every step of viral life cycle. TRIMs can act as intrinsic restriction factors with the ability to interact directly with viral proteins, or they can act indirectly by inducing antiviral cytokines thereby regulating the activity of other antiviral effectors. TRIMs can use different mechanisms to inhibit viral entry, uncoating, replication, or viral release, ultimately resulting in reduction of viral pathogenesis (Fig. [1](#Fig1){ref-type="fig"}). TRIMs that act as restriction factors are usually expressed at sufficient levels to inhibit virus replication, although expression of many TRIMs can be further enhanced by diverse stimuli, including IFNs. A few recent reviews have highlighted the roles of TRIMs in restricting replication \[[@CR3], [@CR30], [@CR31]••\]. **TRIM5α** is one of the best characterized TRIMs acting as a restriction factor against HIV-1 and other retroviruses \[[@CR32]\]. Multiple mechanisms have been proposed for TRIM5α inhibition of retrovirus replication. TRIM5α interacts with the viral capsid through multivalent interactions and inactivates the virus by promoting premature uncoating \[[@CR20], [@CR31]••, [@CR33]\]. Potential mechanisms of viral inhibition that are still under investigation include degradation of the viral capsid by the proteasome, reduced reverse transcription due to premature uncoating, and potentially via induction of innate immunity \[[@CR20], [@CR31]••, [@CR34], [@CR35]\]. Recent reviews explain the detailed molecular mechanisms of TRIM5α antiviral activity \[[@CR20], [@CR36]\]. In addition to HIV-1 restriction, recent reports indicate that TRIM5α also has antiviral activity against specific flaviviruses, including tick-borne encephalitis virus (TBEV), Kyasanur Forest disease virus (KFDV), and Langat virus (LGTV) but not West Nile virus (WNV), dengue virus (DENV), Zika virus (ZIKV), or yellow fever virus (YFV) \[[@CR31]••\]. TRIM5α inhibits RNA replication by promoting proteasomal degradation of the flaviviral NS2B/3 protease and also contributes to the IFN-I mediated antiviral response \[[@CR31]••\]. **TRIM11** is another TRIM that has also been reported to restrict HIV-1 reverse transcription by interacting with the capsid protein and promoting premature uncoating \[[@CR37]\]. **TRIM33** inhibits HIV-1 infection by decreasing HIV-1 integrase function, thus, preventing viral cDNA integration into the host cell genome \[[@CR38]\].Fig. 1The TRIM effect: the forked road of host fitness or susceptibility. The TRIM family of proteins influence how hosts respond to foreign organisms leading to beneficial (host survival) or detrimental (host pathology) outcomes. This duality is linked to whether a particular TRIM retains desirable functions (antiviral or pro-viral participation) and if the negative consequences accompanying TRIM involvement outweigh their positive contributions (failure to tolerate subsequent inflammatory responses)

The targeting of important viral components for destruction by the host has been a defining feature of TRIM-mediated antiviral activity. Ubiquitination and subsequent proteasomal degradation affords the host a means for interrupting the virus life cycle by employing a cell's own garbage disposal system against the invading pathogen. This is the case for hepatitis C virus (HCV), encephalomyocarditis virus (EMCV), hepatitis B virus (HBV), and influenza virus A (IAV). **TRIM22** restricts HCV replication by interacting with the viral NS5A protein and targeting it to the proteasome \[[@CR39], [@CR40]\]. Other viral non-structural proteins like NS2A of JEV are critical for replication, making them desirable targets for TRIMs like **TRIM52** which redirects JEV NS2A to the proteasome \[[@CR41]\]. TRIM22 can also inhibit EMCV by targeting viral 3C protease for ubiquitination and degradation \[[@CR42]\] and inhibits HBV by suppressing the core promoter responsible for viral pre-genomic RNA synthesis \[[@CR43]\]. TRIM14 and TRIM22 have been reported to promote IAV nucleoprotein (NP) ubiquitination, and degradation in a proteasome-dependent manner \[[@CR44], [@CR45]\]. Viral NPs are attractive candidates as TRIM targets as **TRIM41** also recognizes vesicular stomatitis virus (VSV) NP suggesting this system of TRIM redundancy or "cross-talk" may be applicable to other viruses \[[@CR46]\]. The strategy of degrading viral RNA-binding proteins in order to reveal its genome for host detection is a common theme amongst several TRIMs. TRIM21 promotes the destruction of viral capsids via the proteasome and exposes the viral DNA or RNA to cytosolic nucleic acid sensors like cGAS and RIG-I \[[@CR47]\]. In addition to NP, the polymerase complexes of viruses are subject to this means of disposal as **TRIM32** targets the influenza polymerase subunit PB1 of several IAV strains to the proteasome via ubiquitination, while **TRIM21** interacts with the hepatitis B virus (HBD) DNA polymerase to achieve the same effect for ubiquitination and proteasomal degradation \[[@CR48], [@CR49]\].

Aside from utilizing the proteasome, TRIMs have been found to obstruct viruses through various means. In addition to its aforementioned involvement with the proteasome, TRIM21 may act as an intracellular receptor through high-affinity binding with the Fc portion of immunoglobulin (Ig) molecules allowing for restriction of adenoviruses and rhinoviruses \[[@CR50]\]. **TRIM56** was previously shown to inhibit the replication of several viruses in the family *Flaviviridae*, including DENV serotype 2, YFV, bovine viral diarrhea virus, ZIKV, coronavirus OC43, IAV, and HIV-1 \[[@CR51], [@CR52], [@CR53]•, [@CR54], [@CR55]\]. In the case of IAV, TRIM56 blocks IAV replication possibly through interactions with viral RNA \[[@CR55]\]. The proposed method of interaction between TRIM56 and IAV was observed during ZIKV infection where the TRIM56 C-terminal region and E3 ligase activity mediated an association with ZIKV RNA in infected cells \[[@CR53]•\]. Parallels between this study and others can be seen as TRIM41 inhibition of HBV transcription activity also depended on its E3 ligase activity and C-terminal domain \[[@CR56]\]. Furthermore, TRIM interference in vRNA events has proven to be a reliable antiviral method as TRIM22 inhibits HBV by suppressing the core promoter responsible for viral pre-genomic RNA synthesis \[[@CR43]\]. Additional recent studies identifying inhibition of viral proteins by TRIMs included TRIM28 and TRIM59. **TRIM28,** a nuclear protein that is known to have transcriptional regulatory activity \[[@CR57]\] and is a known repressor of endogenous retroviruses \[[@CR58]\], has been recently reported to restrict viral integration of HIV-1 by binding and inhibiting the active, acetylated form of the viral integrase host \[[@CR29], [@CR59]\], while **TRIM59** interacts with the porcine reproductive and respiratory syndrome virus (PRRSV) nsp11 to inhibit infection \[[@CR60]\]. Finally, **TRIM69** inhibits viral transcription and the formation of VSV replication compartments, reducing the synthesis of viral RNA and, therefore, the inhibition of viral replication \[[@CR61]\]. Further, a recent report showed that TRIM69 interacts directly with DENV nonstructural protein 3 (NS3) and drives its polyubiquitination and degradation \[[@CR62]\].

An interesting recent example of a novel TRIM antiviral function independent of its RING domain is **TRIM2**, which is highly expressed in the brain. TRIM2 binds neurofilament light chain (NEFL) subunit through its RBCC and FIL domain. Using *Trim2*^*−/−*^ mice, it was recently shown that TRIM2 suppresses New World arenaviruses (NWA) such as the Junín virus (JUNV) and Tacaribe virus but not Old World arenaviruses such as Lassa or Lymphocytic choriomeningitis virus (LCMV) \[[@CR63]••\]. Consistent with this, fibroblasts from a patient encoding a missense mutation on the CC region of TRIM2 are also more susceptible to this virus infection \[[@CR63]••\]. TRIM2 limits NWA endocytosis into cells and operates at a post-receptor binding step in the viral life cycle. This antiviral activity is dependent on its FIL domain and not TRIM2 E3-Ub ligase activity. A regulatory protein α (SIRPA) was identified by interactome profiling as a TRIM2-interacting protein and also inhibited virus replication. SIRPA's role in preventing phagocytosis is harnessed by TRIM2, resulting in the blockade of JUNV internalization \[[@CR63]••\].

Indirect Antiviral Activity of TRIM Proteins {#Sec3}
============================================

TRIM proteins can also have antiviral activity via indirect mechanisms including induction of antiviral cytokines or regulation of other antiviral effectors. An interesting recent example is **TRIM43**, which was recently shown to inhibit herpesviruses by promoting ubiquitination and proteasomal degradation of the centrosomal protein pericentrin, in turn resulting in nuclear lamina propria-dependent repression of active viral chromatin states \[[@CR64]•\]. However, the majority of studies on TRIM antiviral functions continue to be focused on their potential roles as regulators of innate immune signaling and antiviral cytokine production.

TRIMs in Innate Immunity {#Sec4}
------------------------

The innate immune system is the first line of defense against pathogens as it detects virus invasion and subsequently limits virus replication. Innate immune cytokines released upon virus recognition are responsible for directing a proper adaptive immune response that is involved in elimination of pathogens in the later phase of infection and also shapes immunological memory \[[@CR65]\].

The first step in innate immune activation occurs when pattern recognition receptors (PRRs), including endosomal Toll-like receptors (TLRs) and cytoplasmic RIG-I-like receptors (RLRs), recognize microbial components encoded in microorganism that are known as pathogen-associated molecular patterns (PAMPs) \[[@CR66]\]. PRRs then stimulate a series of downstream signaling cascades that result in the activation and nuclear translocation of transcription factors, such as IRF3, IRF7, and NF-κB, which induce transcriptional upregulation of IFN-I and pro-inflammatory cytokines \[[@CR66]\]. A large number of TRIMs have been found to play important regulatory roles at almost every step in PRR-activated signaling pathways \[[@CR5], [@CR13], [@CR14]\]. In addition, a large number of TRIMs have been found to enhance cytokine signaling pathways \[[@CR5], [@CR13]\].

RIG-I has been thoroughly investigated for its role in virus RNA recognition and its essential role in the antiviral IFN-I response. The structure of RIG-I includes a central helicase domain and a C-terminal domain (CTD), required for RNA binding, and also contains two N-terminal caspase activation and recruitment domains (CARDs) that are essential for downstream signaling. Upon RNA binding, the CARDs undergo conformational changes allowing K63-linked ubiquitination by **TRIM25** \[[@CR67]\], which allows assembly of a signaling complex with mitochondrial antiviral signaling protein (MAVS) at the mitochondria \[[@CR68], [@CR69]\]. TRIM25 has also been reported to have RIG-I-independent antiviral activity to Sindbis virus via the zinc finger antiviral protein (ZAP) \[[@CR70], [@CR71]\]. The ubiquitin ligase activity of TRIM25 may be regulated by direct interactions with endogenous RNA \[[@CR72]•, [@CR73]••\], which also promotes binding to ZAP \[[@CR72]•\]. In addition to TRIM25, other TRIMs and additional E3-Ub ligases have also been reported to ubiquitinate and regulate functions of RIG-I-like receptors. **TRIM4** mediates K63-linked polyubiquitination of RIG-I to positively regulate RIG-I-mediated IFN induction \[[@CR74], [@CR75]\]. **TRIM8** has recently been identified as a modulator of innate signaling in plasmacytoid dendritic cells (pDCs), by protecting IRF7 from proteasomal degradation in an E3-Ub ligase-independent manner \[[@CR76]\]. On the other hand, **TRIM65** has a role in MDA5 K63-linked polyubiquitination by promoting MDA5 activation and oligomerization. Consequently, *Trim65*^−/−^ mice are more susceptible to EMCV infection due to reduced IFN-I induction \[[@CR77], [@CR78]\].

Downstream of RIG-I and MDA5, other TRIMs have also been found to regulate this signaling pathway. **TRIM31** catalyzes K63-linked polyubiquitination of K10, K311, and K461 on MAVS and promotes its aggregation in the mitochondria promoting downstream signaling \[[@CR79]\]. MAVS signaling then leads to activation of different downstream signaling effectors, facilitating the induction of both NF-kB-mediated inflammatory cytokines and IFN-Is. On the NF-kB branch of the pathway, **TRIM5α** has been reported to activate TAK1 kinase via synthesis of unanchored K63-linked polyubiquitin chains, leading to NF-kB and AP-1 activation and inflammatory cytokine induction \[[@CR80], [@CR81]\]. **TRIM23** also mediates activation of NF-kB during human cytomegalovirus (HCMV) infection \[[@CR82]\] and can positively regulate NEMO activity, which is a crucial regulator of NF-κB activation, by mediating K27-linked polyubiquitination \[[@CR83]\].

Another important PRR subject of intense recent studies is the cytoplasmic DNA sensor cyclic GMP-AMP synthase (cGAS), which can recognize a variety of replicating DNA viruses \[[@CR84], [@CR85]\], although studies have also shown that mitochondrial damage during RNA virus infection can result in cytoplasmic DNA leakage \[[@CR86]••\]. The cGAS enzyme catalyzes a reaction to form the second messenger cyclic GMP-AMP (cGAMP), which then binds the adaptor protein STING on the endoplasmic reticulum (ER) and triggers downstream activation of TBK1-IRF3 and NF-kB for subsequent IFN-I and cytokine production \[[@CR85]\]. TRIM proteins can also modulate cGAS-STING signaling. For example, **TRIM14** functions as an adaptor to recruit the deubiquitinating enzyme USP14 and regulate cGAS, improving its stability and enhancing the antiviral response \[[@CR87]\]. **TRIM38** targets cGAS for sumoylation during the early phase of viral infection, preventing its K48-linked polyubiquitination and proteasomal degradation. TRIM38 also sumoylates STING during the early phase of viral infection, promoting both STING activation and protein stability which prevents STING degradation by the chaperone-mediated autophagy pathway \[[@CR88]\]. **TRIM41** has also been proposed to be involved in immune responses induced by DNA viruses and cytosolic DNA, via monoubiquitination of cGAS \[[@CR89]\]. In addition, **TRIM56** can also induce monoubiquitination of cGAS, thereby increasing its ability to interact and sense DNA \[[@CR90]••\] and potentially providing a redundant mechanims of cGAS activation. Interestingly, TRIM56 can also ubiquitinate STING \[[@CR91]\]. The fact that multiple TRIMs have been proposed to modulate both cGAS and STING functions raises the question whether a complex between cGAS-STING and multiple TRIMs (TRIM38, TRIM41, TRIM56) may provide a feedback activation loop that can sustain downtream signaling and may also be functonaly redundant. In addition, the Ub regulatory X domain protein UBXN3B regulates TRIM56-mediated K63-linked polyubiquitination of STING, which is necessary for STING oligomerization and activation of downstream TBK1-mediated antiviral signaling \[[@CR92]\].

Another important immune regulator is **TRIM28**, which, consistent with its known function as a negative regulator of transcription, inhibits expression of pro-inflammatory cytokines and IFN-I; however, infections with highly pathogenic avian influenza viruses (HPAIV), such as H5N1 or H7N7, trigger a PKR-dependent signaling cascade that culminates with phosphorylation of TRIM28 and enhanced cytokine levels during infection \[[@CR93]\]. Interestingly, this anti-inflammatory role of TRIM28 may be associated with its function as a repressor of endogenous retroviruses. For instance, another study identified a loss of sumoylated TRIM28 during IAV infection, which resulted in increased expression of endogenous retroviral elements that can be recognized as a source of "self" dsRNA by the RIG-I pathway \[[@CR94]•\]. These studies highlight the complexity of the pathways that are regulated by TRIMs and the potential indirect effects that TRIMs can have on immune and non-immune pathways.

IFN-I produced during virus infection is then released to the extracellular space and triggers its own signaling cascade in an autocrine or paracrine manner via the IFN receptor (IFNAR). TRIMs have also been implicated in regulation of IFNAR signal transduction. The IKKε kinase has been shown to play a non-redundant role in optimal IFNAR signaling and ISG induction by phosphorylating STAT1 on S708 \[[@CR95]\]. The JAK-STAT signaling pathway is important for defense against viral infection \[[@CR96]\]. Receptor ligation activates the kinases JAK1 and TYK2 and induces phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT2 which together with IRF9 form the interferon-stimulated gene factor 3 (ISGF3) complex, which translocates into the nucleus and induces transcription of an extensive set of antiviral ISGs. **TRIM6** promotes the synthesis of unanchored K48-linked polyubiquitin chains that positively regulate IKKε activity resulting in enhanced IFN-I induction and signaling for optimal ISG induction \[[@CR97]\].

TRIM Proteins in Pathogenesis {#Sec5}
=============================

Although the vast majority of studies have associated TRIM activity with antiviral or innate immune inflammatory functions in response to viral infections, new evidence indicates that TRIMs can also be involved in directly promoting virus replication. This novel function could be a consequence of viruses taking advantage or hijacking TRIMs as a "side-effect" of TRIM-viral protein interaction during the antiviral process, or a direct utilization of the host ubiquitin machinery by the virus to enhance its replication. In either case, these effects exemplify complex mechanism of virus adaption to the host as well as constant interaction between TRIMs and viral proteins during evolution. Recent evidence indicates that some viruses have the ability to hijack TRIMs to improve several steps of the replication cycle, and increased replication would lead to increased pathogenesis. On other hand, increased virus pathogenesis could also be a result of virus antagonizing TRIM-mediated antiviral activity or indirectly affected when dysregulation of specific TRIMs involved in cytokines production results in uncontrolled inflammation and tissue damage (Fig. [1](#Fig1){ref-type="fig"}).

Increased Viral Pathogenesis via Antagonism of TRIM Antiviral Activity {#Sec6}
----------------------------------------------------------------------

### TRIM21 Antagonism during JEV and SFTSV Infection {#FPar1}

TRIM21 can be activated by diverse pathogens like viruses and intracellular bacteria \[[@CR19], [@CR98]\]. After virus detection, TRIM21 synthesizes K63-linked polyubiquitin chains and activates the innate immune pathways NF-κB, AP-1, IRF-3, IRF-7, and IRF-8 \[[@CR19], [@CR98], [@CR99]\], leading to IFN-I production. JEV infection induces the expression of TRIM21 in human microglial cells, which results in attenuation of JEV-mediated effects in terms of activation of IRF-3 and production of IFNβ \[[@CR99]\]. On the other hand, the non-structural (NSs) protein of severe fever with thrombocytopenia syndrome virus (SFTSV) interacts with TRIM21 and inhibits the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) which is responsible for the expression of a series of antioxidant proteins and detoxifying enzymes \[[@CR19], [@CR100], [@CR101]\]. Nrf2 is regulated by interactions with Kelch-like ECH-associated protein 1 (Keap1) and the proteasome system \[[@CR102]\]. In normal conditions, Keap1 targets Nrf2 for degradation which suppresses intracellular antioxidant responses. In context of SFTSV infection, the viral proteins bind to the C-terminal SPRY subdomain of TRIM21, enhancing p62 stability and oligomerization. This allows p62-mediated Keap1 sequestration and activates the Nrf2-mediated antioxidant response, promoting viral replication and pathogenesis \[[@CR103]\].

### Antagonism of TRIM25-Mediated IFN Induction by DENV, MERS-CoV, EBV, and IAV TRIM25 {#FPar2}

A published study identified mutations on the DENV strain PR-2B that emerged during an epidemic in Puerto Rico in the 1990s. These mutations appear to increase production of sub-genomic flavivirus non-coding RNAs (sfRNAs). The PR-2B sfRNAs can bind to TRIM25 and prevent its deubiquitination, which is crucial for TRIM25-mediated activation of RIG-I. These findings suggested that adaptive mutations on DENV sfRNAs have the ability to differentially bind to host antiviral proteins to promote viral evasion of innate immunity and increase viral fitness \[[@CR104]\]. In addition, Middle East respiratory syndrome coronavirus (MERS-CoV) infection suppresses RIG-I ubiquitination and downstream IFN-I and IFN-III induction, via interactions between MERS-CoV N protein and TRIM25 \[[@CR105]•\].

Epstein-Barr virus (EBV) encodes a large tegument protein BPLF1, a viral deubiquitinase (DUB) that facilitates TRIM25's interaction with the 14-3-3 scaffold to promote TRIM25 autoubiquitination and sequestration to inhibit IFN-I responses \[[@CR106]\].

The IAV-NS1 protein also has the ability to antagonize the immune response by blocking TRIM25-mediated RIG-I ubiquitination \[[@CR107]\]. IAV isolates from different species may have varying abilities to inhibit IFN-I induction partly due to differential NS1-TRIM25 and NS1-Riplet interactions that may contribute to differences in pathogenicity between avian, swine, and human IAV isolates \[[@CR108]\].

### Viruses Targeting TRIM23 {#FPar3}

An intriguing example of a TRIM being targeted specifically by a virus is TRIM23, which has been shown to ubiquitinate the NS5 protein of YFV \[[@CR109]\]. This ubiquitination provides YFV-NS5 the ability to interact with STAT2, which ultimately results in inhibition of IFN-I signaling and increased virus replication. Interestingly, other studies have shown that TRIM23 has antiviral activity and this is dependent on NEMO leading to IRF3 and NF-kB activation and IFN-I induction \[[@CR83]\]. Since YFV NS5 binds STAT2 only after IFN-I treatment \[[@CR109]\], it suggests that TRIM23-mediated ubiquitination of YFV NS5 versus NEMO are regulated by different mechanisms. Reports indicate that YFV and DENV NS5 protein have 10 residues in their N-terminal regions, which are essential for the IFN antagonism function \[[@CR109], [@CR110]\]. TRIM23 has also been reported to have a function in autophagy-mediated antiviral defense mediated by TANK-binding kinase 1 (TBK1) \[[@CR111]\]. Autophagy is an evolutionarily conserved process that restricts certain intracellular pathogens \[[@CR112]\]. However, herpes virus simplex-1 (HSV-1) inhibits autophagy to enhance its replication in the mucosal epithelium and establish latency in neurons of the peripheral nervous system \[[@CR113]\]. This inhibition is caused by the HSV-1 US11 protein which interacts with TRIM23 and blocks the formation of the functional TBK1. The TRIM23 complex is required for autophagy induction \[[@CR114]\]. These data provide a new insight into viral escape from autophagy-mediated host restriction mechanisms.

### TRIM6 Function in IFN-I Induction and Signaling during Nipah Virus and West Nile Virus Infections {#FPar4}

TRIM6 has been shown to play multiple roles during infections with different viruses, leading to protection or pathogenicity depending on the conditions. TRIM6 can play a role in optimal IFN-I-mediated antiviral function against different RNA viruses, including IAV, EMCV and Sendai virus (SeV) \[[@CR97]\]. In addition, the Nipah virus (NiV) matrix (M) protein has been described to interact with and degrade TRIM6 \[[@CR115]\]. In NiV-infected cells, the endogenous level of TRIM6 is decreased significantly compared with mock cells or cells infected with a recombinant NiV lacking M \[[@CR115]\]. IFN promoter luciferase reporter assays demonstrated that NiV-M can inhibit TRIM6's function in IFN-I induction and signaling, but the functional importance of this antagonism was not tested in the context of NiV infection \[[@CR115]\] **(**Fig. [2b](#Fig2){ref-type="fig"}**)**. Several other NiV proteins act as potent antagonists of the IFN-I induction and signaling pathways \[[@CR116]--[@CR118]\], including NiV accessory protein V which interacts with human TRIM25 to prevent activation of RIG-I and downstream IFN-I induction \[[@CR119]\]. NiV-M's interaction with and degradation of TRIM6 may play a redundant role in IFN-I antagonism, but it cannot be excluded that the NiV-M-TRIM6 interaction plays an uncharacterized pro-viral function or antagonizes a distinct TRIM6-regulated pathway. In the context of West Nile virus (WNV), TRIM6 is required for efficient IFN-I induction and signaling to dampen replication **(**Fig. [2b](#Fig2){ref-type="fig"}**)** \[[@CR97], [@CR120]\]. TRIM6 was found to be required for the phosphorylation of STAT1 at S708 and the induction of several ISGs known to be involved in WNV antagonism \[[@CR120]\]. Additionally, TRIM6 regulates the expression of VAMP8, a vesicle-associated membrane protein we found to be required for optimal JAK1 phosphorylation downstream of IFN-I stimulation \[[@CR120]\]. Therefore, TRIM6 is emerging as an important antiviral factor via the IFN-I system.Fig. 2Pro-viral and antiviral roles of TRIM6. **a** TRIM6 facilities the ubiquitination (white circles with Ub) of Ebola virus (EBOV) VP35 at lysine residue 309 (K309). This ubiquitination at K309 augments the EBOV VP35's polymerase co-factor activity in the presence of TRIM6. **b** Upon virus infection, viral RNA in the cytoplasm triggers the activation of RIG-I-like receptors, including RIG-I and MDA-5, to trigger downstream type-I interferon (IFN-I) induction. TRIMs 6 and 25 both participate in the IFN-I pathway. TRIM6 promotes the synthesis of unanchored K48-linked polyubiquitin chains which act as a scaffold for IKKɛ oligomerization promoting its kinase activity and downstream functions in IFN-I induction and signaling, and TRIM6 regulates that expression of a vesicle-associated protein, VAMP8, which has been shown to promote JAK1 phosphorylation downstream of IFN-I signaling. TRIM25 facilities the covalent conjugation of K63-linked polyubiquitin to RIG-I to promote RIG-I's activity. The viral antagonism (red arrows) of these TRIMs' function has been described for EBOV VP35 and Nipah virus (NiV) accessory protein V (V) and matrix protein (M). In addition to the antagonism of TRIMs, these viral proteins also target additional steps of the IFN-I pathways, including NiV-V antagonism of MDA5 and STAT1 and EBOV antagonism of IKKɛ- and TBK1-mediated phosphorylation of IRF3

Increased Viral Pathogenesis by TRIMs Direct Pro-viral Activity {#Sec7}
---------------------------------------------------------------

### TRIM6 Pro-viral Function {#FPar5}

TRIM6 has been identified as an important host factor targeted to enhance Ebola virus (EBOV) replication. EBOV is a highly pathogenic virus that causes severe hemorrhagic fever in humans \[[@CR121]\]. VP35 is the viral polymerase co-factor \[[@CR122], [@CR123]\] and an IFN-I inhibitory protein \[[@CR122], [@CR124]--[@CR126]\] critical for EBOV replication and pathogenesis. We found that TRIM6 ubiquitinates EBOV VP35 to promote optimal viral replication \[[@CR16]••\] (Fig. [2a](#Fig2){ref-type="fig"}). Using co-immunoprecipitation assays and IFN-I reporter assays, we found that VP35 antagonizes TRIM6-mediated enhancement of IFN-I induction and TRIM6 facilitates ubiquitination of VP35 at K309. Using an EBOV minigenome system \[[@CR122]\], it was shown that TRIM6 enhances the minigenome activity when expressed with wild-type (WT) VP35 but not a K309A mutant \[[@CR16]••\]. Further, a TRIM6 ubiquitin ligase mutant (C15A) is unable to enhance VP35 polymerase co-factor activity \[[@CR16]••\]. Despite EBOV VP35's capability to antagonize TRIM6-mediated IFN-I activation, EBOV replication was attenuated significantly in TRIM6-KO cells compared with WT cells \[[@CR16]••\]. Although the VP35 may interact with TRIM6 to antagonize IFN-I induction, VP35 exploits TRIM6 as pro-viral factor to enhance viral replication. However, TRIM6 knockout cells infected with EBOV express higher levels of the pro-inflammatory cytokine IL-6 as compared with WT cells \[[@CR16]••\], indicating that TRIM6 may also play a role in regulating inflammation and could lead to the immune dysregulation observed during EBOV infection. The mechanism underlying TRIM6's pro-viral activity versus its immune regulatory role is under on-going investigation. In addition to VP35 residues, other VP35 lysine residues are also ubiquitinated \[[@CR16]••\], but their identity, function, and dependence on TRIM6 are yet to be determined.

### TRIM7 in Pathogenesis {#FPar6}

TRIM7 is another E3-Ub ligase that can promote virus pathogenesis or protect against infection depending on the context of virus infection. We recently reported that the envelope (E) protein of ZIKV is K63-linked polyubiquitinated by TRIM7, promoting enhanced replication in brain and reproductive tissues and leading to enhanced pathogenesis in vivo \[[@CR17]••\]. Since a proportion of ubiquitinated E is present in infectious viruses and ubiquitinated E-containing viruses infect cells more efficiently, this appears to create a more permissive environment for its replication within specific target tissues (Fig. [3a--b](#Fig3){ref-type="fig"}**)**. Indeed, a recombinant infectious ZIKV mutant that lacks ubiquitination on the K38 residue (ZIKV-E K38R) has reduced ability to attach to host cells (Fig. [3b](#Fig3){ref-type="fig"} and [c](#Fig3){ref-type="fig"}**\#1**), leading to reduced virus-endosome membrane fusion (Fig. [3c](#Fig3){ref-type="fig"}**\#2**), and lower replication as compared with WT ZIKV, causing less pathology. TRIM7 may play a role in determining ZIKV tissue tropism in vivo, because ZIKV replicated to lower titers in brain and reproductive tissues (uterus and testis) as compared with other tissues of *Trim7*^*−/−*^ mice and as compared with WT littermate controls \[[@CR17]••\]. Cell fractionation experiments suggested that TRIM7 and its E2-Ub conjugase UbcH5a \[[@CR127], [@CR128]\] co-localize in the endoplasmic reticulum (ER) compartment in ZIKV infected cells, although TRIM7 can also re-localize to the Golgi \[[@CR17]••, [@CR129]\], suggesting that TRIM7 may be hijacked by ZIKV-E during maturation in the Golgi or during replication in the ER (Fig. [3c](#Fig3){ref-type="fig"}**\#3**).Fig. 3**a** A portion of released Zika virions possess ubiquitinated envelope proteins. Zika virus grown in both human and mosquito cells are ubiquitinated to varying degrees with human grown viruses having longer poly-Ub chains while mosquito-grown viruses retain shorter poly-Ub chains. **b** Envelope ubiquitination by TRIM7 enhances Zika virus entry in mammalian, but not mosquito, hosts. Ubiquitination of the Zika envelope protein at site K38 is made possible by the E3 ubiquitin ligase TRIM7 allowing for enhanced Zika tissue tropism where levels of TRIM7 are high (brain, uterus, and testis). **c** Ubiquitination of Zika envelope promotes binding to host receptors and enhances viral entry. The K63-poly-Ub chains of Zika envelope afford for stronger interactions with host receptors (\#1), virus-endosome membrane fusion (\#2), and higher replication titers (\#3). Upon Zika infection, TRIM7 re-localizes to the Golgi and co-localizes with Zika envelope in distinct puncta where ubiquitination presumably occurs. Infectious Zika virions with ubiquitinated envelope can be neutralized with K63-regulate innate immune responses in both a positive and negative manner. TRIM7 promotes herpes virus infection by targeting STING for K48-poly-Ub and proteasome-mediated degradation (\#5) while hindering norovirus replication (\#6). Additionally, TRIM7 can also enhance TLR4 signaling in macrophages during LPS challenge (\#7)

Once ZIKV virions are ubiquitinated by TRIM7, they are released from infected cells (Fig. [3c](#Fig3){ref-type="fig"}**\#4**) and such ubiquitination provides an advantage for viral replication by promoting more efficient attachment to cellular receptors (Fig. [3c](#Fig3){ref-type="fig"}**\#1**). Additional evidence that ZIKV infectious particles contain ubiquitinated E comes from experiments showing that an anti-K63-Ub antibody can neutralize ZIKV replication in cells and in vivo \[[@CR17]••\] (Fig. [3c](#Fig3){ref-type="fig"}**\#4**). Although multiple receptors are proposed to be involved in ZIKV attachment and cell entry, including DC-SIGN, AXL, Tyro3, and TIM-1 \[[@CR130]\], we demonstrated that at least in the case of TIM-1, efficient ZIKV attachment depends on the presence of K63-linked polyubiquitinated E in the infectious ZIKV particles. This is also supported by data showing that infection of *Havcr-1*^*−/−*^ mice (*Havcr-1* is the gene that encodes TIM-1 protein), with ZIKV-E WT, exhibited a reduction in viral titer in the brain as compared with WT littermate controls, whereas no difference was observed with the ZIKV-E K38R mutant virus. This suggests that although Tim-1 is not the only receptor that mediates ZIKV entry, it may play a role in specific cell types/tissue when ZIKV contains ubiquitinated E (Fig. [3b](#Fig3){ref-type="fig"} and [c](#Fig3){ref-type="fig"}**\#**1**)** \[[@CR17]••\].

Interestingly, although mosquitoes also express components of the ubiquitin system, including a small number of TRIM orthologues, ZIKV grown in mosquito cells appears to contain reduced and shorter forms of polyubiquitinated E and this does not affect virus replication in live mosquitoes \[[@CR17]••\] (Fig. [3a](#Fig3){ref-type="fig"}--[b](#Fig3){ref-type="fig"}**)**. However, previous reports indicate that the mosquito ubiquitin Ub3881 protein may be involved in DENV E protein degradation \[[@CR131]\] although other studies have also proposed that virus replication in mosquitoes may be dependent on a functioning ubiquitin proteasome system \[[@CR132]\]. Nonetheless, the role of the ubiquitin system and the function of individual E3-ubiquitin ligases during infection and in mosquito transmission are still unclear.

TRIM7 in known to be involved in some important biological processes including tumor cell proliferation and glycogen metabolism \[[@CR129], [@CR133]\]. TRIM7 has also been shown to act as an E3 ligase mediating K63-linked polyubiquitination of the AP-1 coactivator RACO-1, leading to RACO-1 protein stabilization \[[@CR127]\]. Other studies have also proposed that TRIM7 may play antiviral roles against norovirus \[[@CR134]•\] (Fig. [3c](#Fig3){ref-type="fig"}**\#6**) and in IFN induction \[[@CR135]••\], which is also in line with our own findings that TRIM7 KO cells have reduced IFNβ induction upon ZIKV infection or PRR stimulation, the data from in vivo infections in *Trim7*^*−/−*^ mice suggest that the pro-viral roles of TRIM7 are dominant over its potential IFN-mediated antiviral roles in specific cell types and in vivo \[[@CR17]••\]. In addition, TRIM7 was also recently described to negatively regulate responses to DNA viruses by targeting STING for degradation \[[@CR136]•\] (Fig. [3c](#Fig3){ref-type="fig"}**\#5**), so TRIM7 could also play a role in alternative innate immune signaling pathways during ZIKV infection, especially if DNA damage occurs during virus infection that could lead to activation of the cGAS-STING pathway.

Since ubiquitination was observed on residue K38, which is conserved in members of the *Flaviviridae* family, and we also found that DENV particles also contained ubiquitinated E \[[@CR17]••\], it will be interesting to see if other enveloped viruses may use similar mechanisms of virus entry via interactions between potentially ubiquitinated envelope resident protein and host receptors.

Conclusions {#Sec8}
===========

This review describes the roles of TRIMs in virus-host interactions and TRIM involvement in immune signaling and direct virus restriction. In addition, viral antagonism of TRIMs exemplifies the importance of this protein family in antiviral responses. Despite these advancements, many TRIMs have yet to be characterized. Additionally, viruses hijack similar innate immune host factors to enhance their replication. More needs to be learned regarding the role of TRIMs in adaptive immunity. A new area of investigation is whether additional antiviral TRIMs may be redirected by others pathogens to improve replication through protein ubiquitination. This information could help design novel broad-spectrum antiviral strategies, including targeting TRIM function that may cause hyper-inflammation. To this end, more studies using in vivo animal models will be required to differentiate between antiviral and pro-viral roles of TRIMs and ultimately elucidate whether virus-induced pathology could be treated using pharmacological approaches to inhibit specific TRIM activity.
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